Biomarker-Based Diagnosis
in Neurocognitive Disorders
A training initiative by ESMIT on behalf of the European Association of Nuclear Medicine (EANM).
A new ESMIT educational initiative
NUCLEAR MEDICINE IN
BIOMARKER-BASED DIAGNOSIS
OF NEUROCOGNITIVE DISORDERS
Alzheimer’s and other dementias are a growing health challenge. Early biomarker-based diagnosis is key – and nuclear medicine plays a central role. AD-LEARN helps professionals close knowledge gaps and apply consistent workflows across Europe.
Join the project and become a part of the professional’s community
Explore our online courses, access valuable resources, and engage in live events with leading experts in the field. Together, we can enhance patient outcomes and shape the future of dementia care.
Docs and tools
Learn Anytime, Anywhere
The core of AD-LEARN is delivered through the ESMIT eLearning platform, the educational hub of the European Association of Nuclear Medicine (EANM). Our 10 online modules are fully CME-accredited and designed to be accessible, interactive, and practical for busy healthcare professionals.
In our system, you’ll find much more:
For whom
AD-LEARN is designed for the multidisciplinary community involved in diagnosing and managing neurocognitive disorders.
Neurologists & Psychiatrists
Technologists & Radiographers
Nurses
Researchers
Students & Trainees
Why this matters?
Functional imaging methods are not optional extras — they are irreplaceable tools in modern dementia diagnostics. To ensure equitable, patient-centred care, all professionals must share a common standard of knowledge.
By aiming at more than 1,000 healthcare professionals across Europe, AD-LEARN aims to:
Close the identified healthcare gap in nuclear medicine training.
Ensure consistent, evidence-based practice across countries.
Build a stronger community of experts ready to face the dementia challenge.
Check out the latest news
Stay up to date with the latest developments from the AD-LEARN project. In this section, we share updates on project milestones, upcoming activities, survey launches, and key outcomes. You will also find highlights from related initiatives and events in the field of Alzheimer’s disease, ensuring professionals and stakeholders remain informed about progress and opportunities to engage.